| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2767 | Ite-conhch3 | Novel highly potent (EC 50 = 1.6 nM) aryl hydrocarbon receptor (AhR) agonist with high affinity (K i = 88 nM) |
|
| DCC2768 | Itf3756 | Novel Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitor, showing a remarkably low toxicity both in vitro and in vivo and increasing the function of regulatory T cells (Tregs) at well-tolerated concentrations |
|
| DCC2769 | Itf3985 | Novel selective HDAC6 inhibitor |
|
| DCC2770 | ith12246 | Novel PP2A ligand, protecting against memory impairment and focal cerebral ischemia in mice |
|
| DCC2771 | Ith12505 | Novel neuroprotective agent |
|
| DCC2772 | Ith15004 | Novel, potent, selective, and BBB-permeable P2X7 antagonist |
|
| DCC2773 | Itx-4520 | Novel highly potent, orally bioavailable hepatitis C virus (HCV) entry inhibitor |
|
| DCC2774 | Ityr-dbrmd | First-in-class iodothyronine deiodinase type 3 (DIO3) inhibitor, demonstratig attenuated cell counts, induction in apoptosis, and a reduction in cell proliferation in DIO3-positive HGSOC cells (OVCAR3 and KURAMOCHI) |
|
| DCC2775 | Ivabradine | Selective inhibitor of the funny channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium |
|
| DCC2776 | Ivde77 | The first Ang IV-analogue being able to abolish IRAP-availability completely at the cell surface in vitro |
|
| DCC2777 | Ivq Hydrochloride | Prodrug of QVO, being quickly converted to QVO in mice and rats following administration, ameliorating hyperglycemia, and suppressing hepatic gluconeogenesis and activating AMPK signaling pathway in the liver tissues |
|
| DCC2778 | Iwp-051 | Novel, orally available soluble guanylate cyclase (sGC) stimulator with once-daily dosing potential for the treatment of cardiovascular diseases |
|
| DCC2779 | Iwp2g9 | Novel WNT inhibitor, suppressing cytoplasmic and nuclear biochemical markers of WNT signaling in cultured cells, inhibiting recombinant TNKS activity, or WNT fatty acylation |
|
| DCC2780 | Iwr107 | Novel WNT inhibitor, suppressing cytoplasmic and nuclear biochemical markers of WNT signaling in cultured cells, inhibiting recombinant TNKS activity, or WNT fatty acylation |
|
| DCC2781 | Iy-iy-das | Novel potent noncleavable proteolysis targeting chimeric (PROTAC) for TrkC degradation in metastatic breast cancer cells |
|
| DCC2782 | Iy-iy-ss-das | Novel potent and cleavable proteolysis targeting chimeric (PROTAC) for TrkC degradation in metastatic breast cancer cells |
|
| DCC2783 | J-2156 Tfa Salt | Potent and selective agonist of human somatostatin receptor 4 (sst4), reducing mechanosensitivity of peripheral nerve afferents and spinal neurons in an inflammatory pain model |
|
| DCC2784 | Jak1-in-38a | Novel highly potent JAK1-selective inhibitor, exhibiting excellent selectivity over JAK2, JAK3, and TYK2 (IC 50 : JAK1 0.145 nM; JAK2 2.94 nM; JAK3 2.31 nM; TYK2 8.17 nM) |
|
| DCC2785 | Jak1-in-b61 | Novel JAK1 inhibitor |
|
| DCC2786 | Jak2-in-7j | Novel selective Jak2 inhibitor, demonstrating a time-dependent knock-down of pSTAT5, a downstream target of Jak2 |
|
| DCC2787 | Jak3-in Tricyclic-1 | Novel irreversible selective JAK3 inhibitor through the covalent interaction with a Jak3 active-site cysteine |
|
| DCC2788 | Jak3-in Tricyclic-2 | Novel irreversible selective JAK3 inhibitor through the covalent interaction with a Jak3 active-site cysteine |
|
| DCC2789 | Jak3-in Tricyclic-3 | Novel irreversible selective JAK3 inhibitor through the covalent interaction with a Jak3 active-site cysteine |
|
| DCC2790 | Jak3-in-4 | Novel Selective JAK3 Inhibitor with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket |
|
| DCC2791 | Jak3-in-5 | Novel Selective JAK3 Inhibitor with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket |
|
| DCC2792 | Jak-in-1 | Novel potent JAK1/2/3 inhibitor |
|
| DCC2793 | Jak-in-3 | Novel potent JAK1/3 inhibitor, targeting JAK3 and JAK1 with IC 50 at 3nM and 5nM, respectively |
|
| DCC2794 | Jami1001a | Novel positive allosteric modulator of AMPA receptor |
|
| DCC2795 | Jamunone M | Novel anti-triple-negative breast cancer (anti-TNBC) agent with a high selectivity against BC cells over normal human cells, downregulating phosphatidylinositide 3-kinase (PI3K)/Akt pathway by suppressing protein-tyrosine phosphatase 1B (PTP1B) expression |
|
| DCC2796 | Janelia Fluor 526, Se | Novel fluorogenic yellow fluorescent dye for use in self-labeling tag systems |
|
